IRIS UniCatt

Guidi, Luisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.487
NA - Nord America 2.460
AS - Asia 915
SA - Sud America 159
AF - Africa 18
Continente sconosciuto - Info sul continente non disponibili 3
Totale 6.042
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.430
DE - Germania 969
SE - Svezia 452
CN - Cina 357
SG - Singapore 302
UA - Ucraina 237
IT - Italia 196
FR - Francia 163
BR - Brasile 151
IE - Irlanda 127
GB - Regno Unito 117
IN - India 79
ID - Indonesia 75
FI - Finlandia 61
RU - Federazione Russa 39
PL - Polonia 36
TR - Turchia 32
BE - Belgio 25
CA - Canada 20
NL - Olanda 14
IR - Iran 13
HK - Hong Kong 12
JP - Giappone 10
CI - Costa d'Avorio 7
CZ - Repubblica Ceca 7
AT - Austria 6
KR - Corea 6
ES - Italia 5
PT - Portogallo 5
BG - Bulgaria 4
CH - Svizzera 4
GR - Grecia 4
HU - Ungheria 4
PH - Filippine 4
AR - Argentina 3
LT - Lituania 3
MA - Marocco 3
MX - Messico 3
PK - Pakistan 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BD - Bangladesh 2
BN - Brunei Darussalam 2
BZ - Belize 2
DK - Danimarca 2
EG - Egitto 2
GT - Guatemala 2
JM - Giamaica 2
LV - Lettonia 2
SA - Arabia Saudita 2
TN - Tunisia 2
TW - Taiwan 2
VN - Vietnam 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AZ - Azerbaigian 1
CG - Congo 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EU - Europa 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
NO - Norvegia 1
OM - Oman 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 6.042
Salva come PNG Salva come JPEG
Città #
Chandler 554
Singapore 207
Ashburn 185
Jacksonville 167
Dublin 124
San Mateo 122
Dearborn 107
Ann Arbor 101
New York 91
Jakarta 73
Nanjing 71
Wilmington 62
Cattolica 59
Nürnberg 59
Boston 52
Munich 43
Los Angeles 41
Milan 41
Bremen 34
Houston 34
Princeton 34
Lawrence 33
Beijing 32
Izmir 27
Moscow 27
Marseille 24
Brussels 23
Lancaster 22
Seattle 22
Fairfield 21
Kraków 21
Nanchang 20
Woodbridge 19
Redwood City 18
Shenyang 17
Hangzhou 15
Warsaw 15
Augusta 14
Boardman 14
Changsha 14
Frankfurt am Main 14
Helsinki 14
Guangzhou 13
Leawood 13
Hefei 12
London 12
Mountain View 12
Shanghai 12
Hebei 11
Jiaxing 11
Rome 11
Kunming 10
The Dalles 10
Tianjin 10
Detroit 9
Hong Kong 9
Norwalk 9
Pune 9
Redmond 9
São Paulo 9
Toronto 9
Zhengzhou 9
Ardabil 8
Costa Mesa 8
Hyderabad 8
Abidjan 7
Andover 7
Cagliari 7
Düsseldorf 7
Lauterbourg 7
Nuremberg 7
San Jose 7
University Park 7
Fremont 6
Jinan 6
Ottawa 6
San Francisco 6
Seoul 6
Tokyo 6
Washington 6
Brasília 5
Indiana 5
Portsmouth 5
Rio de Janeiro 5
Sacramento 5
Amsterdam 4
Falkenstein 4
Kish 4
Manaus 4
Millbury 4
Sofia 4
Belo Horizonte 3
Bengaluru 3
Berlin 3
Brno 3
Cambridge 3
Edinburgh 3
Lanzhou 3
Newark 3
Phoenix 3
Totale 3.094
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 328
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 162
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 155
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 153
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 150
Early atherosclerosis in patients with inflammatory bowel disease. 147
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 147
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 144
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 138
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 136
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 134
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 127
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 125
Sonography of the small bowel after oral administration of fluid: an assessment of the diagnostic value of the technique 120
Use of infliximab in particular clinical settings: management based on current evidence. 113
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 113
Ileal Crohn's disease: CEUS determination of activity 113
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 109
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 108
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 106
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 103
Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy 102
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 99
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 96
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 93
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 89
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 87
Management of perianal fistulas in Crohn's disease: an up-to-date review 86
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 86
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 84
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 79
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 78
AID in aging and autoimmune diseases 77
Mucosal healing in ulcerative colitis: surveillance or colectomy? 76
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 75
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 75
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 72
Adalimumab in active ulcerative colitis: a "real-life" observational study 71
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 68
Neuropeptide Y plasma levels and immunological changes during academic stress 67
Paradoxical arthritis occurring during anti-TNF in patients with Inflammatory Bowel Disease: histological and immunological features of a complex synovitis. 67
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 66
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 64
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. 63
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 63
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 62
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 62
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 61
The Italian registry of therapeutic apheresis: Granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study 59
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 59
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 58
[Soluble factors with immunosuppressive activity in human neoplasms] 57
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 56
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 55
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 53
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 52
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 51
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 50
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 50
Linking estrogen receptor β expression with inflammatory bowel disease activity 49
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 49
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 48
Watery stools and metabolic acidosis 48
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. 46
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 45
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 45
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 41
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. 37
Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis 29
Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: A single-centre experience 24
Serum levels of metalloproteinases and their inhibitors in nonalcoholic steatohepatitis 21
Small bowel diseases 16
Small bowel diseases 15
Totale 6.112
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.271
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.271
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020146 0 0 0 0 0 0 0 0 0 0 102 44
2020/2021480 21 49 15 56 59 11 44 17 60 17 117 14
2021/2022646 55 45 9 107 16 14 8 116 19 27 106 124
2022/20231.376 184 193 96 233 109 159 54 115 172 10 33 18
2023/2024639 30 185 18 46 17 112 25 38 10 22 62 74
2024/2025947 23 42 117 18 122 46 37 65 156 123 198 0
Totale 6.112